Amryt Pharma Plc – Further Expansion in Middle East

6 March 2018

Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has further expanded its market coverage for Lojuxta® (lomitapide) with an exclusive distribution agreement for Lebanon, Jordan and Syria. The agreement is with Pharaon Healthcare-Droguerie Mercury S.A.L. (“Pharaon Healthcare”), one of the leading full-service distributors in the region.


The Company estimates that there are approximately 40 patients with Homozygous Familial Hypercholesterolaemia (“HoFH”) in the countries covered by this agreement, with Lebanon in particular having a pronounced “founder effect” and therefore materially higher prevalence of HoFH.


Lojuxta is a therapy used to treat adult patients with HoFH, the rare, life-threatening, genetic cholesterol disorder.


Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said:


“This is Amryt’s fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria. Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians’ requests regarding their patients suffering with HoFH.”





Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO

Rory Nealon, CFO/COO

Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark Percy


Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell


Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison


KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson


About Amryt Pharma plc



Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.


The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolaemia, which impairs the body’s ability to remove LDL cholesterol (“bad” cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels.  If left untreated, heart attack or sudden death may occur in childhood or early adulthood.


Amryt’s lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment.  It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.


Amryt’s earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.


The Company joined AIM and Dublin’s ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.


Pharaon Healthcare


Part of Pharaon Group, PHARAON HEALTHCARE is a well-established full-service distributor, with a significant position in the Middle East. With its origins dating back to 1939, it has expertise in regulatory affairs, marketing, sales and distribution in Pharmaceuticals, Nutritionals, Consumer Care and Medical Supplies and Equipment.


Companies in Pharaon Group, operate under the following operating principles:

Implement strong corporate culture
Integrate market and partner needs and commit to and reach high goals
Enhance quality and productivity, maintain state-of-the-art technologies and tools in our activities and provide training and professional growth opportunities to our teams
Develop leadership by taking pride in what we do and inspiring others, empower managers and encourage responsibility and entrepreneurship
Develop corporate social responsibility by doing what is right for our community and our stakeholders.
Having always in mind delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.



This information is provided by RNS

The company news service from the London Stock Exchange